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Tests in Identifying Germ Cell Mutagens and
Putative Nongenotoxic Carcinogens
by M. D. Waters,1 H. F. Stack,2 M. A. Jackson,2 and
B. A. Bridges3
For more than a decade, mutagenicity tests have had a clearly defined role in the identification ofpotential
human mutagens and an ancillaryrole inthe identification ofpotential human carcinogens. The efficiency of
short-term tests in identifying germ cell mutagens has been examined usingacombined dataset derived from
the U.S. Environmental Protection Agency/International Agency for Research on Cancer Genetic Activity
Profile (EPA/IARC GAP) andEPAGene-Toxdatabases. Ourreviewofthesedataindicates adequate sensitivity
of batteries of in vitro short-term mutagenicity tests in identifying germ cell mutagens. The analysis also
supportsthe inclusionofanin vivo assayassuggestedinproposedregulatorytestingguidelines. Inthecontext
ofcarcinogenicity testing, the ability ofshort-term bioassays to detectgenotoxic ormutagenic carcinogens is
wellestablished. Suchtestsare notconsideredtobeassensitivetonongenotoxicornonmutageniccarcinogens.
However,analysespresented inthisreportusingtheEPA/IARCGAPdatabasedemonstratethatmanyputative
nongenotoxic carcinogens that have been adequately tested in short-term genetic bioassays induce gene or
chromosomal mutation or aneuploidy. Further investigation should reveal whether the mutagenicity ofthese
agents plays an important mechanistic role in their carcinogenicity.
Introduction
Inregulatorypractice, mutagenicity tests have aclearly
defined, primary role in the identification of potential
human mutagens and an ancillary role, when considered
with otherrelevant toxicological information, in the identi-
fication ofpotential human carcinogens. Certain assump-
tions have been made in the deployment ofthese tests for
the detection of germ cell mutagens. For example, all
substances capable ofmutatingmammalian germcells are
viewed as being able to mutate somatic cells in vivo. It is
also assumedby manythatthegreatmajority of(ifnotall)
substances capable of mutating somatic or germ cells of
mammals can be detected with in vitro tests. Two in vitro
tests (one for bacterial mutagenicity and one for chromo-
some breakage in cultured mammalian cells) are assumed
tobe sufficient to detect amajority ofmutagens. However,
the alternative of an additional test (induction of gene
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mutations in cultured mammalian cells) is considered by
some to be preferable, either as a complement to the two-
testbatteryorinlieuofinvitrocytogeneticswhencarried
outusing aprotocol thatpermits evaluation ofclastogeni-
city.
Because ofthepurported sensitivityofinvitro systems
and the desire to reduce the requirement for animal
testing,testsinvolvingmammaliangermcellsarenotused
for screening purposes. It has generallybeen regarded as
prudent, however, to require at least one in vivo mam-
malian mutagenicity test for substances with relatively
high human exposure, such as food additives and drugs.
The detection of chromosome breakage (aberrations or
micronuclei) in rodent bone marrow has been the test of
choice.
How Well Do Short-Term Tests Detect Germ
Cell Mutagens?
Mutagenicity tests have now been used for regulatory
purposes for more than a decade. In the intervening time,
a body of data has accumulated in the literature that
permits a retrospective assessment oftheperformance of
short-term tests in the detection ofpresumptive germ cell
mutagens. Therefore, we have produced a combined data
set and addressed a number ofspecific questions regard-WATERS ET AL.
ing the ability of short-term tests to detect such agents.
The results ofour analysis indicate an acceptable level of
sensitivity for the detection of germ cell mutagens and
suggestsomewaysinwhichthetestsmightbedeployedin
the future.
How Well Do Short-Term Tests Detect
Carcinogens?
As mentioned above, an ancillary role of short-term
testsandonethathasprovokedmuchcontroversy(1)isthe
detection of potential human carcinogens. The utility of
short-term testsinthe detection oftheso-called genotoxic
carcinogens has not been seriously questioned. However,
the earlier tauted overall correlations between muta-
genicityin short-termtestsandcarcinogenicityinrodents
have deteriorated since the 1970s. The apparent failure of
short-term tests in the detection of carcinogens may be
attributed in part to the identification of more and more
putative nongenotoxic carcinogens. These agents often
induce site-selective carcinogenicity in rodents when
administered at or close to the maximum tolerated doses
(2). Although short-term tests are not considered to be
sensitive to such agents, the overall database for the
putative nongenotoxic carcinogens has not been carefully
examined.
From a mechanistic perspective and in the context of
risk assessment, it is of obvious importance to be able to
distinguish between "genotoxic" and "nongenotoxic" car-
cinogens. In recent years, much attention has focused on
the detection and definition ofthe latter group of agents.
Ashbyand Tennant(3)recognized thatmostnongenotoxic
carcinogens are not detected in the Ames test and are
devoid of alerting (DNA reactive) structural features.
Theyused the combination ofpositive results in theAmes
test and the presence of structural alerts as an index of
genotoxicity. Butterworth (4)broadened the definition ofa
genotoxic agent as "one for which a primary biological
activity ofthe chemical or ametabolite is alteration ofthe
information encoded in the DNA ... point mutations,
insertions, deletions or changes in chromosome structure
ornumber." Conversely, Butterworth (4) defined nongeno-
toxic chemicals as "those that lack genotoxicity as the
primary biological activity. While these agents may yield
genotoxic events as a secondary result of other induced
toxicity, such as forced cellular growth, their primary
action does not involve reactivity with the DNA."
In this report we carefully examine a group ofputative
nongenotoxiccarcinogens andclassifythemonthebasisof
their mutagenicity per se (ability to induce alterations in
DNA structure or content). We have defined criteria for
evidence ofmutagenicity (and nonmutagenicity) and have
applied these criteria to 66 agents that have been cited as
nongenotoxic in the pablished literature (3-7). Three end
points (gene mutation, chromosomal aberration, and
aneuploidy) were used to evaluate the mutagenicity of
these agents. The data clearly demonstrate that many of
the putative nongenotoxic carcinogens that have been
adequately tested in short-term bioassays induce gene or
chromosomal mutations or aneuploidy.
Methods
In approachingthefirst analysis (detection ofgermcell
mutagens),wehaveconsideredthosesubstancesforwhich
peer-reviewed evidence ofgerm cell mutagenicity is avail-
able.TheprimarydatasourcewastheU.S. Environmental
Protection Agency/International Agency for Research on
Cancer Genetic Activity Profile (EPA/IARC GAP) com-
puterprogram (available fromM.D.W.),whichwas supple-
mented with data from the EPA Gene-Tox database (now
available on TOXNET). These peer-reviewed databases
(8,9)wereconstructed usingtheavailablepublishedlitera-
ture and contain a preponderance ofpositive data.
For our purposes we have assumed that the muta-
genicitytestresultswerebeingusedpredictivelytoscreen
for germ cell mutagens and we therefore present an
analysis ofthe sensitivity ofthese tests in detecting germ
cell mutagens. We have not been able to perform an
analysis on the specificity of short-term mutagenicity
tests, i.e., their performance with substances that are
established as nonmutagenic to mammalian somatic cells
or germ cells in vivo.
The use of short-term tests in mutagenicity testing is
nottodefine agermcellmutagenbutrathertoindicatethe
potential to cause germ cell mutations. The agent mustbe
shown to reach the germinal tissues to satisfy the pre-
sumption that it is a germ cell mutagen. Most published
germ cell mutation data have been derived from the eval-
uation of substances known to be carcinogenic or muta-
genic in vitro or to be structurally related to such sub-
stances.
The data used for the second analysis (detection of
putative nongenotoxic carcinogens) are from the GAP
database only.Alistwas compiled of66 agents citedinthe
published literature (3-7) as putative nongenotoxic car-
cinogens. Fifty-three ofthese agents were present in the
GAPdatabase, and 39 ofthesewererepresentedbyfive or
more testresults (Salmonella tester strains considered as
individualtests).Atablewas constructed forthe39 agents
emphasizing mutagenicity, i.e., gene mutation, chromoso-
mal aberration, and aneuploidy. Each test result was
verified by carefully reviewing the original publication
from which data had been extracted. A summary tabular
matrix was then prepared based on the strength of the
positive data.
The following criteria were applied to the results in
assessing the evidence ofmutagenicity (or nonmutageni-
city) in vivo or in vitro: a) Evidence of mutagenicity in
vivo is provided when an agent exhibits activity in at least
two tests for one or more ofthefollowing end points: gene
mutation, chromosomal aberration, or aneuploidy and
positive results are obtained in at least one mammalian
study in vivo; b) Evidence of mutagenicity in vitro is
provided when an agent exhibits activity in at least two
tests in vitro for one or more of the above end points. c)
Evidencefornonmutagenicityinvitroisprovidedwhenan
agent demonstrates negativeresults in tests representing
all three end points above and includes one mammalian
test in vitro for gene mutation and one for chromosomal
aberration. d) Evidence for nonmutagenicity in vivo is
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provided when an agent demonstrates negative results in mutagen. There are obvious limitations to this standard.
tests representing all three end points above and includes In many cases only one test has been used, and confirma-
a minimum of two mammalian studies in vivo. tory testing is warranted. Moreover, in some instances
reviewers may have been overly generous in their accep-
Results and Discussion tance of the data. All mammalian germ cell mutagens for
which data from relevant in vitro tests were available are
Efficiency of Short-Term Tests in shown in Tables 1 and 2. Although protocol adequacy and
Identifying Germ Cell Mutagens thequalityofthedataaremajorconsiderationsforregula-
tory purposes, this analysis deals onlywith the qualitative
The germ cell assays that comprise the standard to test results. These data have been peer reviewed and are
which other tests are compared are shown in Tables 1 and accepted forthe purposes of our present analysis. In afew
2. For analytical purposes, a positive result in any ofthese cases, new data have been added based on the recent
tests is considered to define a mammalian germ cell publishedliterature.
Table 1. Substances identified as mammalian germ cell mutagens and
the test results from the EPAJIARC Genetic Activity Profile database."
Germ cell mutation' Mammalian cells Bone marrow
SLP
01'
Agents SLO CCC CGC CGG COE DLM DLR MHT Ames Test CA GM CA or MN
Bleomycin + + + + + +
Cisplatin + + + + + +
Cyclophosphamide + ± + + + + + + + + +
Ethylene oxide + + + + + + + +
Myleran - - + + + + + +
Thiotepa + + + + + + + + +
Adriamycin + + + + +
Aflatoxin B, - ± ± + ±
BCNU + ? - + + + +
Benzo[L lpyrene + + + + +
Nitrogen mustard +l- + + + +
Potassium dichromate + + + + +
6-Mercaptopurine + ? + + + +
Chloramphenicol + + - - + + +
Diethyl sulfate + + + + + NA
Procarbazine HCl + ? - + NA + +
Tliaziquone + + + + + NA +
Azathioprine + + + NA +
CCNU + + + + NA
Chlorambucil +" + + + NA
Chloroprene + + + NA - +
Acetaldehyde + + + NA NA
N-Butyl glycidyl ether + + NA NA +
Dibromochloropropane - + + + NA NA
Furosemide + - + + NA
Mercuric chloricde - - + - + + NA
Chloromethane + + NA + NA
Diazepam + - - NA +
Saccharin, sodium - + - ± +
Trimustine + NA NA + NA
Ethanol - + + + - +
Norethisterone acetate + - - NA NA
Tris(2-chloroethyl) + - NA - NA
phosphate
DDT + - + - ? - ?
Abbreviations: Mouse specific locus tests: SLP, postspermatogonial and SLO, other stages; chromosomal aberrations in 'io: CCC, spermatocytes
treated and observed; CGC, spermatogonia treated and spermatocytes observed; CGG, spermatogonia treated and observed, and COE, oocytes or
embryos; dominant lethal tests: DLM, mice; DLR, rats; MHT, mouse heritable translocation test; CA, chromosomal aberrations; GM, gene mutation;
MN, micronuclei.
'Positive (+), negative (-), and conflicting (?) test results are indicated; NA, not available.
"Germ cell results have been updated for chloroambucil (10) and nitrogen mustard (11).
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Table 2. Substances identified as mammalian germ cell mutagens and
the test results from the Gene-Tox Program.a
Germ cell mutation Mammalian cells Bone marrow
Agents SLT CCC CGC CGG COE DLT MHT Ames Test CA GM CA or MN
l-Ethyl-l-nitrosourea + + + + + +
Ethyl methanesulfonate + + + + + + +
Methyl methanesulfonate + + + + + + + + +
Mitomycin C + + + + + + + + +
Methotrexate + + + + +
1-Methyl-l-nitrosourea + - + + + + NA
Captan + - + NA + +
Hyeanthone methane- - + + NA + +
sulfonate
nTimethyl phosphate + + + NA +
Isopropyl methanesulfonate + + + NA NA + +
TEriethylenemelamine + + + + + NA + NA +
TEPA + + + + NA NA
Hexametapol + NA - + +
N-Ethylnitrosouirethane + + NA NA NA
Fotrin + NA + NA NA
2-OH-nitrosourea + + NA NA NA
METEPA + NA NA NA +
Nitrogen mustard N-oxide + + NA NA NA
Streptonigrin + NA + NA NA
Triflupromazine + NA + NA
Acrylamide + + + - NA NA +
Ergotamine tartrate + - NA NA NA
Octyl adipate + - NA NA NA
Abbreviations: SLT, mouse specific locus tests; chromosomal aberrations in vivo: CCC, spermatocytes treated and observed; CGC, spermatogonia
treated and spermatocytes observed; CGG, spermatogonia treated and observed; COE, oocytes or embryos; DLT, dominant lethal tests; MHT, mouse
heritable translocation test; CA, chromosomal aberrations; GM, gene mutation; MN, micronuclei.
"Positive (+), negative (-), and conflicting (?) test results are indicated; NA, not available.
"Acrylamide results are updated from the riecent literature (12-14).
As shown in Figure 1, results from the combined GAP
and Gene-Tox databases are as follows: Of 56 germ cell
mutagens, 52hadbeensubjected tobacterialmutagenicity
and/or in vitro mammalian cell chromosome breakage
assays, and ofthese 87% gave apositive result. Evaluation
ofthose substances forwhichbothtestsweredone showed
that 32 out of 34 mutagens were detected. The two sub-
stances not identified as mutagens by this battery
(diazepam and norethisterone acetate) depended on a
single mammalian germ cell test (dominant lethal) for
theirinclusion in the germ cell mutagen list. These agents
are not well studied but, like ethanol (negative in a wide
range ofmutagenicity assays), have been shown to cause
malsegregation ofchromosomes (aneuploidy), which could
account for the dominant lethal results.
Ifatestformammalian cell mutagenesis is added to the
above two tests, the following results are obtained. Ofthe
germ cell mutagens tested in one or more of the three
tests, 87% were identified as mutagens, i.e., three addi-
tional positives were identified. Analysis ofsubstances for
which all 3 tests were performed showed all 26 were
identified as mutagens. Although these figures are mar-
ginally higher than those for the two-test battery, the
difference reflects the more restricted number of com-
pounds tested.
Because one of the most widely used gene mutation
assays (selecting for thymidine kinase deficiency in
L5178Y mouse lymphoma cells) also responds to chromo-
some deletions formed by chromosome breaking agents,
there is in principle no reason why a mammalian gene
mutation assay such as this should not be used to replace
the in vitro cytogenetics and mammalian cell mutagenesis
assays described above. This combination, i.e., bacterial
mutation test and mammalian cell gene mutation assay
(with a protocol for assessment ofchromosome breakage),
demonstrates the following results. As shown in Figure 1,
of 52 substances tested in either one or both of tests just
described, 42 were positive. Of the 34 that were tested in
both tests, 30 were identified as mutagens. These figures
are similar to those for the previous two test batteries,
which suggests (albeit based on arelatively small data set)
that the use ofthe cheaper mammalian cell gene mutation
assay as an alternative to the assay for mammalian cell
chromosome breakage deserves consideration. The four
germ cell mutagens missed were DDT, sodium saccharin,
ethanol, and tris(2-chloroethyl) phosphate (Fig. 1).
Given that a clear positive result in any of the tests
mentioned above is normally enough to warrant a require-
ment for an in vivo assay, is itnecessary to doboth in vitro
assays if the first one done is positive and, if not, which
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assay should be done first? As shown in Figure 1, there is
no doubt that the mammalian cell chromosome breakage
assay identifies more accurately the germ cell mutagens
(93%) than does the bacterial mutation assay (75%). [The
mammalian cell gene mutation assay is also high (86%)].
The mammalian cell chromosome breakage test, although
the more sensitive, is also more expensive. Acase could be
made forperformingthebacterial mutagenicity testfirst,
and only performing a mammalian cell chromosome
breakage assay if a negative result is obtained.
In view ofthe fact that there are bacteria in the gut of
mammals and that the liver may be able to carry out
metabolic transformations that cultured cells cannot, even
with S-9 microsomal fraction, it seems prudent at the
present time to subject bacterial mutagens to in vivo
testing. Thiswould normallyinvolve lookingfortheinduc-
tion of chromosome breakage in cells of the rodent bone
marrow, either scoring micronuclei or broken chromo-
somes at metaphase. The rationale for this is that not all
substances that aremutagenic invitro areable to express
significant mutagenic activity in the whole animal. Bone
marrowassaysarepreferred becausetheyarewidelyused
and reliable and because it is reasoned that a mutagen
capable of reaching the gonads ought also to reach the
bone marrow. We may therefore ask whether the data
showthatgermcellmutagens areasubsetofbonemarrow
mutagens.
Asshownin Figure1,of36germcellmutagenstestedin
a bone marrow assay (either aberrations or micronuclei),
IN VITRO
33 were identified as mutagens. The 3 not identified were
ethanol, sodiumsaccharin, andtriflupromazine.Adlerand
Ashby (15) found the evidence for germ cell mutagenicity
of sodium saccharin and triflupromazine questionable.
Sodium saccharin is usually included in lists ofreference
nongenotoxic carcinogens. Ethanol (also reviewed by
these authors) may act by inducing aneuploidy, which the
bone marrow assays were notdesigned to detect. Obe and
Anderson (16) state that ethanol shows strain dependent
differences in the bone marrow assays. Overall, the data
are consistent with the view that germ cell mutagens are
probably not unique and that some of the bone marrow
assays in the database were not performed using current
protocols andthereforewere notofadequatepower(17). It
should be noted that the bone marrow assay detects not
only substances shown to cause chromosomal damage in
rodent germ cells, but also those known to induce gene
mutations in the specific locus coat color test. This
reinforces the generalization that specific gene (as dis-
tinctfromchromosomal) mutagens arerare. Thus, there
is some security in using an in vivo chromosome break-
age assay for presumptive germ cell mutagens. Adler
and Ashby (15) concluded that "the general observation
that rodent germ cell mutagens are also genotoxic in
somatic cells in vivo remains valid." We would only add
the comment that the problem of strain variability
amongrodents contributes tothe discrepancieswithtri-
flupromazine and ethanol and is an underlying problem
in all oftoxicology.
IN VIVO
Bone Marrow Cytogenetics
MAMMALIAN BACTERIAL MAMMALIAN
CELL CHROM. GENE CELL GENE
A T IC
ABERRATION MUTATION MUTATION ABERRATIONS MICRONUCLEI
37/40 = 93% Posfitve 36/48=759% Pos. 32137 = 86# Poshive 19/25 = 76% Pos_iv 29/34 = 85% Positive
Either Test: 45/52 = 87% Positive
Both Tests: 32/34 = 94% Positive
Negatives (both tests): Diazepam,
Norethisterone Acetate
Either Test: 33/36 = 92°h Positive
Both Tests: 16/18 = 89% Positive
Negatives (eithertest): Ethanol,
Na Saccharin, Triflupromazine
Any Test: 48/55 = 87% Positive
All 3 Tests: 26/26 = 100% Positive
No agent missed in all 3 tests
Either Test: 42/52 = 81% Positive
Both Tests: 30/34 = 88% Positive
Negatives (both tests): Na Saccharin, DDT,
Ethanol, Tris(2-chloroethyl) phosphate
FIGURE 1. Test performances are given for the germ cell mutagens from the combined EPA/IARC GAP and Gene-Tox databases. Performance is
indicated by the fraction ofagents with positive test results divided by the number ofagents tested and is expressed also as the percentage positive.
Combinations ofshort-term tests are illustrated by the range of arrows.
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Evidence of Mutagenicity ofPutative
Nongenotoxic Carcinogens
Using the criteria for evidence of mutagenicity pres-
ented in Methods, we were not successful in segregating
the putative nongenotoxic carcinogens into onlyfour cate-
gories. Thus, the word "limited" was added to identify
those agents that met most ofthe stated criteria. Figures
2 and 3 present a summary ofthe short-term test results
for the 39 agents that could be grouped according to the
resulting six categories of evidence. The qualitative data
for these agents are presented according to the three
genetic end points; gene mutation, chromosomal aberra-
tion, and aneuploidy. Amiscellaneous category is included
for data on cell transformation and sister-chromatid
exchange. Test systems are identified bythree-letter code
words (see appendix for definitions) and in vitro tests are
separated frominvivotestsforeachendpoint. Ingeneral,
the agents investigated fall into two groups: 23 agents
showing evidence ofmutagenicity (9 ofwhich are included
in the limited evidence category), and 16 agents showing
evidence of nonmutagenicity, (14 of which show limited
evidence). It should be noted that essentially all of these
compounds are negative in the Ames test (exceptions are
chlorodibromomethane with conflicting results, and nitri-
lotriacetic acid [NTA], not tested). Furthermore, struc-
tural alerts are identified only for p-chloro-o-toluidine,
BENZENE
MONURON
TRICHLOROETHYLENE
DIETHYLSTILBOESTROL
P-CHLORO-O-TOLUIDINE
2,4,5-T
NITRILOTRIACETIC ACID
MALONALDEHYDE
ASBESTOS
PHENOBARBITAL
2,4-D
SACCHARIN, SODIUM
P,P'-DDE
CHLOROTHALONIL
ANIUNE
CHLORODIBROMOMETHANE
CHLORDANE
HEPTACHLOR
DDT
DIETHYLHEXYLPHTHALATE
SACCHARIN
2,3,7,8-TCDD
2,4,6-TRICHLOROPHENOL
aniline, chlorodibromomethane, and carbon tetrachloride
(3,18).
Evidence ofMutagenicity. The positive data for the
seven agents that display evidence ofmutagenicityin vivo
(Fig. 2) represent primarily chromosomal effects (chro-
mosomal aberrations and/or micronuclei in mouse bone
marrow) or, in the case of diethylstilbesterol (DES) and
NTA, induction of aneuploidy. Although induction of
aneuploidy does not necessarily indicate that a chemical
has interacted directly with DNA, clearly, a structural
genetic alteration (alterationin DNAcontent) hasresulted
from chemical treatment. Results of cell transformation
and sister chromatid exchange assays generally streng-
then the case for classifying these compounds as a group.
Aswith theprevious category, the seven agents display-
ing evidence ofmutagenicity in vitro exhibit a large body
of positive data for chromosomal mutation; all except
asbestos appear to be eukaryotic gene mutagens as well.
Three agents, malonaldehyde, 2,4-D, and p,p'-DDE, are
gene mutagens in Drosophila and in mammalian cells in
culture but not in bacteria. The inclusion of all seven
agents within the category of in vitro evidence is sup-
portedbypositive datafromcelltransformation and sister
chromatid exchange assays.
Agents listed in the category of limited evidence for
mutagenicity are classified as such because ofconflicting
results or, moreoften,weakpositiveresponses, frequently
GENE MUTATION CHROM. ABERRATIONS ANEUPLOIDY MISCELLANEOUS
IN VITRO IN VIVO IN VITRO IN VIVO IN VITRO IN VIVO IN VITRO IN VIVO
SSSSSESDD GGGGGG: M MCCC MCCCDDMC SDAA: A TTTT SSS SS
AAAAACCMM 995511 S I I I H :VBGG LLH L CMI I' V BCCR I H: VL
05789WRMX HOT1AH T ACR L :MACGMRTH NNAH: A MMSR CR L AH
EVIDENCE OF MUTAGENICITY IN VIVO
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FIGURE 2. Summary ofshort-term test results for 23 putative nongenotoxic carcinogens displaying evidence ofmutagenicity.
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ETHINYLOESTRADIOL
DECABROMODIPHENYL OXIDE
1.4-DIOXANE
NORETHISTERONE ACETATE
PENTACHLOROETHANE
1,1,1,2-TETRACHLOROETHANE
PBB
17B-OESTRADIOL
HEXACHLOROCYCLOHEXANE
HEXACHLOROBENZENE
MELAMINE
CARBON TETRACHLORIDE
RESERPINE
TETRACHLOROETHYLENE
PCB
MCPA
* Positive O Conflicting
* Weak Positive 0 Negative
FIGURE 3. Summary ofshort-term test results for 16 putative nongenotoxic carcinogens displaying evidence ofnonmutagenicity.
fortwo or more endpoints.Agents in this category should
not be considered to pose a serious mutagenic hazard.
Evidence ofNonmutagenicity Only 2 agents, poly-
chlorinated biphenyls (PCB) and (4-chloro-2-methyl-
phenoxy)acetic acid (MCPA) (shown at the bottom ofFig.
3), clearly conform to the criteria for evidence of non-
mutagenicity in vivo. Negative test results representing
all three end points are reported for these 2 compounds
including two or more in vivo mammalian studies for
chromosomal aberrations. The remaining compounds are
listed under the categories of limited evidence for non-
mutagenicity in vitro (6 agents) and limited evidence of
nonmutagenicity invivo (8 agents). Thelimitations reflect
inadequate testing for the three genetic end points. The
agents showing evidence of nonmutagenicity are not as
thoroughly tested as are those agents with evidence of
mutagenicity. Nonetheless, these 16 compounds may be
considered as nonmutagenic carcinogens based on the
data available in the EPA/JARC GAP database.
AsummaryofNTPandIARCevaluations ofanimaland
human carcinogenicity classifications for the 39 putative
nongenotoxic carcinogens presented in this paperis given
inFigure4. The NTPevaluations arepresentedbyspecies
and sex together with the number of the NTP Technical
Report from which the information was obtained. The
IARC evaluation represents animal and human studies as
well as an overall evaluation ofthe carcinogenic potential
for humans. Possible mechanisms of carcinogenesis are
also indicated (refer to Conclusions).
Based on IARC's evaluation of 22 of the remaining 27
agents forwhich there was insufficient mutagenicity data
for inclusion in this analysis, 17 are "not classifiable as to
carcinogenicityin humans" and theremainder are consid-
ered as "possibly carcinogenic to humans." Limited evi-
dence of mutagenicity and carcinogenicity for these
agents suggests that it may be inappropriate to classify
them as nongenotoxic carcinogens at present.
Overall,when comparing agentswith evidence ofmuta-
genicity to those showing evidence of nonmutagenicity
(Fig. 4), it is difficult to find any remarkable distinctions
between the two groups based on the weight-of-evidence
for carcinogenic:ty. Closer examination of the NTP car-
cinogenicity data yields similar results. Figure 5 shows a
graphic representation of the data organized by tumor
site, species, and sex. The first column indicates evidence
ofmutagenicity or nonmutagenicity. Again, no clear rela-
tionship was apparent between the carcinogenicity of
these agents in any site and their mutagenicity in short-
term tests. The data do show, however, that 7 of11 mouse
hepatocarcinogens tested are nonmutagenic, and this
observation warrants further investigation.
Finally, attempts were made to assess the relationship
between mutagenicity and potential mechanisms of car-
cinogenesis (Fig. 4). Various kinds of biological activity
have been associated with the nongenotoxic carcinogens
including enhanced cell proliferation (resulting from
cytotoxicity or mitogenesis), hormonal changes, tumor
promotion, and peroxisome proliferation. Six peroxisome
proliferators (7) were identified among the agents evalu-
ated in this study. Four of these, (2,4,5-trichloro-
phenoxy)acetic acid (2,4,5-T), (2,4-dichlorophenoxy)acetic
acid (2,4-D), diethylhexylphthalate, and trichloroethylene
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MECH. COMPOUNDS
NTP
b
TR# MR FR MM FM
IARC0
H A EVAL MONO.
FIGURE 4. Summary of NTP and IARC carcinogenicity evaluations. Compounds are organized according to the evidence of mutagenicity or
nonmutagenicity as shown in Figures 2 and 3.
aPotential mechanism ofaction, A: peroxisome proliferation; B: cell proliferation (cytotoxic); C: cell proliferation (mitogenic); D: hormonal action; E:
tumor promotion.
bHeadings are,TR#: Technical Report No. MR: malerats; FR: femalerats; MM: malemice; FM: femalemice; carcinogenicityevaluation, *positive;
0 limited; C equivocal/insufficient; 0 negative. [National Toxicology Program Technical Reports, NTP, Research Triangle Park, NC (27)].
'Headings are, H: human data; A: animal data; EVAL: overall evaluation; MONO: IARC Monographs volumes. IARC overall evaluation, 1:
carcinogenic to humans; 2A: probably carcinogenic to humans; 2B: possibly carcinogenic to humans; 3: not classifiable as to its carcinogenicity to
humans. [International Agency for Research on Cancer, Lyon, France (28)].
dNTP data are from studies with p-chloro-o-toluidine, HCI; malonaldehyde, Na salt; and aniline, HCI.
eIARC summarized the carcinogenicity data for DDT and its metabolites but only evaluated DDT.
displayed evidence of mutagenicity (Fig. 2), while MCPA
and 1,1,1,2-tetrachloroethane did not (Fig. 3). Similarly,
two of five cytotoxins (4), NTA and sodium saccharin,
showed evidence of mutagenicity (Fig. 2), but carbon
tetrachloride, pentachloroethane, andtetrachloroethylene
did not (Fig. 3). One ofthree mitogens (4), phenobarbital
(Fig. 2), was considered mutagenic while polybrominated
biphenyls (PBB) and hexachlorocyclohexane showed lim-
ited evidence ofnonmutagenicity in vivo (Fig. 3). 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD), identified as a pro-
moter that appears to act through specific receptors (4),
showed limited evidence of mutagenicity (Fig. 2). Three
hormones (ethinylestradiol, norethisterone acetate, and
17,B-estradiol) are represented among agents showing
limited evidence of nonmutagenicity in vivo (Fig. 3) and
one (diethylstilbestrol [DES]) is listed with agents show-
ing evidence ofmutagenicity in vivo (Fig. 2). Thus, multi-
ple putative mechanisms ofcarcinogenicity are suggested
forthemutagenic aswell as thenonmutageniccarcinogens
represented in Figures 2 and 3, respectively.
Conclusions
Dearfield et al. (19) have discussed recently the testing
approaches used bythe EPAOffice ofPesticide Programs
(OPP) and Office of Pollution Prevention and Toxics
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Salmonella + In Vitro + In Vivo Bone
Gene Mutation Marrow Cytogenetics
* Aberrations
or
* Micronuclei
In Vitro Gene Mutation (choice):
(a) Mouse lymphoma L5178Y cells, TK locus,
small and large colonies
(b) Chinese hamster ovary cells, strain AS52
(c) Chinese hamster ovary cells or lung fibroblasts
with the appropriate in vitro test for clastogenicity
FIGURE 6. EPA's Office ofPesticide Program's mutagenicity test guide-
line.
(OPPT). The scheme outlined in Figure 6 represents the
proposed OPP mutagenicity test guideline. The first two
components in the guideline essentially represent the
three-test battery previously discussed (Fig. 1). The in
vivo tests in the OPP screening battery include the same
bone marrow assays (aberrations or micronuclei) men-
tioned above.
Under the OPPT testing scheme shown in Figure 7, the
initialbatteryis essentiallythe same asthat ofthe OPP as
discussed above. Most chemicals would require no further
testingiffound negative in allthree ofthe tests inthefirst
tier. However, subsequent germ cell tests or cancer bio-
assays maybewarranted based on otherinformation such
as human exposure, compelling chemical structure-
activityrelationships, or other factors of concern. Positive
testresults in theinitialtierwould triggerfurther testing
in the second tier; additionalpositive results in the second
Salmonella + In Vitro
Gene Mutation
Interaction with Gonadal DNA
Specific Locus Test
+ In Vivo Bone
Marrow Cytogenetics
* Aberrations
or
* Micronuclei
Dominant Lethal
Heritable Translocation
Visible
or
* Biochemical
FIGURE 7. The Office of Pollution Prevention and Toxics mutagenicity
test scheme.
tier tests would trigger the appropriate germ cell tests.
The results of the present analysis lend support to the
regulatorystrategyformutagenicitytestingthathasbeen
outlined by the EPA. There are additional implications in
terms ofcarcinogenicity testing as discussed below.
In any sizeable series of chemicals subjected to muta-
genicity testing, two groups of agents will be found that
are mutagenic in vitro but that are not mutagenic to
mammalian germ cells. The first group are those that
produce chromosomal damagein therodentbonemarrow.
These (or their active metabolites) may not penetrate to
the gonads butmustbe presumed to have the potential to
produce chromosomal damage in somatic tissues in vivo.
The regulatory position is that, in the absence ofevidence
to the contrary, it is prudent to assume that any chemical
capable of causing mutations in vivo in mammals is a
potential carcinogen. Inthe light ofthisview, itwas in the
past rare to proceed to a mammalian germ cell assay
becausetheavailablemutagenicityinformationwasgener-
ally considered sufficient for regulation based on carcino-
genicpotential. The newregulations mentioned above will
require further eValuation of mutagenic potential per se.
The second group ofcompounds is more difficult to deal
with. They are those that are positive in vitro but that do
not produce detectable chromosome damage in the bone
marrow. This group will include some that are not
absorbed, are not activated in vivo, or are immediately
inactivated or detoxified. These may be presumed not to
present a mutagenic or genotoxic hazard in animals or in
man. Others, however, will be active, but their active
species do not reach the bone marrow. The gut and the
liver are clearlypotential targets for such agents. Most of
the evidence for such "local" activity pertains to direct-
acting alkylating agents. Ashby (20) has pointed out how
unwiseitis to neglectthese agentsbecause their genotox-
icityis notsystemic.Thetypicalregulatorypositionisthat
further work is needed to provide reassurance that there
is no mutagenic or genotoxic action in the gut orliver. The
nature ofsuchworkis determined on acase-by-casebasis.
The techniques currently available often leave much to be
desired in terms of reproducibility, and many have not
been adequately validated. Some of the most difficult
problems in genetic toxicology occur in this area, and it is
one inwhich high hopes are held for the future application
ofrecently developed assays with transgenic mice.
Another problem area in genetic toxicology is that of
interpreting short-term tests results for putative non-
genotoxic carcinogenswithregard tohazardidentification
and risk assessment. It is difficult to ignore the positive
mutagenicity test results reported for many ofthe agents
discussed in this report, even in light ofevidence that the
carcinogenicity of some of them may be mediated pri-
marily through nongenotoxic mechanisms (4). Unless an
agent has been tested for each ofthe three broad catego-
ries ofDNA alterations, i.e., gene mutation, chromosomal
aberration and aneuploidy, it is inappropriate to conclude
that the compound is nonmutagenic. Similarly, the
strength ofthe evidence for carcinogenicity must also be
carefully evaluated. For example, malonaldehyde is
obviouslymutagenic in vitro, but the evidence ofcarcino-
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genicity is weak. Thus, IARC lists malonaldehyde as "not
classifiable as to its carcinogenicity in humans," and the
NTP data show a lowincidence oftumor formation in the
ratthymus gland (Fig. 4).AshbyandMorrod (2) notethat
many nongenotoxic agents induce selective carcinogeni-
city in rodents after treatments at or close to the
maximum-tolerated doses and that the activity of these
compounds inhumans cannotalwaysbe assumed. Sodium
saccharininducesbladdertumorsinratsadministered5%
saccharin in the diet (21), a dose much higher than the
levels present in normal human diets. The evaluation of
humanrisksassociatedwithexposurestosuchcompounds
must be performed on a chemical-by-chemical basis con-
sidering not only the strengths and weaknesses of the
mutagenicity data but ofthe carcinogenicity data aswell.
Moreresearchisneeded onthemechanisms ofaction of
the putative nongenotoxic carcinogens to ensure proper
evaluation of these agents in the context of quantitative
riskassessment. Manybiologicalactivitiesmayormaynot
berelevanttotheultimate mechanisms ofcarcinogenicity.
For example, a number of putative nongenotoxic rodent
hepatocarcinogens have been shown to cause peroxisome
proliferation (7). Although peroxisome proliferation has
been demonstrated in most rodent species tested, nonhu-
manprimates areonlyweaklyresponsive, suggestingthat
humans are at limited risk of carcinogenic effects due to
this phenomenon (22-25). Other compounds, such as car-
bon tetrachloride, chloroform, tetrachloroethylene, pen-
tachloroethane, and sodium saccharin, appear to produce
tissue damage by cytotoxicity resulting in regenerative
hyperplasia (26). The specific mechanisms involved or the
conditionsunderwhichthese agentsproducetheireffects,
as mentioned earlier in the case ofsodium saccharin, may
have little ifany relationship to human cancer risk.
In summary, the efficiency of current procedures for
screeningmutagens has been examined using acombined
data set derived from the EPA/IARC GAP and Gene-Tox
databases. Our review of these data indicates that the
sensitivity of the batteries of in vitro short-term muta-
genicity tests currently used to identify potential germ
cell mutagens is approximately 90%. Some possible
improvements inthe deployment ofsuch tests, such asthe
inclusion of a mammalian assay for induction of
aneuploidy, are worthy of further exploration. However,
the data affirm the utility of short-term tests in hazard
identification and support current regulatory testing
strategies.
In the context ofcarcinogenicity testing, the ability of
short-termteststo detectgenotoxic ormutagenic carcino-
gens is well established. Such tests are not viewed as
sensitive to nongenotoxic or nonmutagenic carcinogens.
Analyses presented in this report (Fig. 2) usingthe EPA/
IARC GAP database, however, demonstrate that many
putative nongenotoxic carcinogens that have been ade-
quatelytestedinshort-termgeneticbioassaysinducegene
or chromosomal mutation or aneuploidy. The ability of
compounds toinduce suchalterationsin DNAstructure or
content cannot be ignored as work continues toward
understanding the mechanisms of carcinogenesis and
potential cancer risks for human populations. Further
investigation ofthe agents listedin Figure 2 shouldreveal
whethertheirmutagenicityplays animportantmechanis-
tic role in their carcinogenicity.
Appendix
Short-Term Test Code Definitions
Test code
AIA
AIH
AVA
CBA
CCC
CGC
CGG
CHL
CIC
CIR
CLH
COE
DLM
DLR
DLT
DMM
DMN
DMX
ECW
GIA
GIH
G5T
G51
G9H
G90
MHT
MIA
MST
MVM
SAO
SA5
SA7
SA8
SA9
SCN
SCR
SHL
SIC
SIR
SLH
SLP
SLO
SLT
SVA
TBM
TCM
TCS
TRR
Definition
Aneuploidy, animal cells in vitro
Aneuploidy, human cells in vitro
Aneuploidy, animal cells in vivo
Chromosomalaberrations, animalbone-marrowcellsinvivo
Chromosomal aberrations, spermatocytes treated in vivo,
spermatocytes observed
Chromosomal aberrations, spermatogonia treated in vivo,
spermatocytes observed
Chromosomal aberrations, spermatogonia treated in vivo,
spermatogonia observed
Chromosomal aberrations, human lymphocyte in vitro
Chromosomal aberrations, Chinese hamster cells in vitro
Chromosomal aberrations, rat cells in vitro
Chromosomal aberrations, human lymphocytes in vivo
Chromosomal aberrations, oocytes or embryos treated in
vivo
Dominant lethal test, mice
Dominant lethal test, rats
Dominant lethal test (Gene-Tox)
Drosophila melanogaster, somatic mutation (and recom-
bination)
Drosophilia melanogaster, aneuploidy
Drosophila melanogaster, sex-linked recessive lethal test
Escherichia coli WP2 uvrA, reverse mutation
Gene mutation, other animal cells in vitro
Gene mutation, human cells in vitro
Gene mutation, mouse lymphoma L5178Y cells, tk locus
Gene mutation, mouse lymphoma L5178Ycells, all otherloci
Gene rnutation, Chinese hamster lungV-79 cells, hprt locus
Gene mutation, Chinese hamster lung V-79 cells, ouabain
resistance
Mouse heritable translocation test
Micronucleus test, animal cells in vitro
Mouse spot test
Micronucleus test, mice in vivo
Salmonella typhimurium TA100, reverse mutation
Salmonella typhimurium TA1535, reverse mutation
Salmonella typhimurium TA1537, reverse mutation
Salmonella typhimurium TA1538, reverse mutation
Salmonella typhimurium TA98, reverse mutation
Saccharomyces cerevisiae, aneuploidy
Saccharomyces cerevisiae, reverse mutation
Sister chromatid exchange, human lymphocytes in vitro
Sister chromatid exchange, Chinese hamster cells in vitro
Sister chromatid exchange, rat cells in vitro
Sister chromatid exchange, human lymphocytes in vivo
Mouse specific locus test, postspermatogonial
Mouse specific locus test, other stages
Mouse specific locus test (Gene-Tox)
Sister chromatid exchange, animal cells in vivo
Cell transformation, BALB/c 3T3 mouse cells
Cell transformation, C3H 1OT1/2 mouse cells
Cell transformation, Syrian hamster embryo cells, clonal
assay
Cell transformation, RLV/Fischer rat embryo cells
The authors acknowledge the review and constructive comments pro-
videdbyI.-D.Adler,J.Ashby,H.V.Malling, R.W.Tennant,andS. Nesnow
and the typing skills of B. Linthicum. The research described in this
article has been reviewed by the Health Effects Research Laboratory,
U.S. Environmental Protection Agency and approved for publication.
Approval does not signifythatthe contents necessarily reflectthe views
and policies ofthe Agency nor does mention oftrade names or commer-
cial products constitute endorsement or recommendation for use.
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